Approaches to enhance the GBM immunity by depletion of immunosuppressive macrophages or with CSF-1R inhibitor PLX3397 showed limited efficacy in a preclinical GBM murine model 39 or a clinical trial of recurrent GBM patients 40. Here, CSF1R is linked to glioblastoma.